Tris Pharma Inc., a therapeutic products maker based in Monmouth Junction, has acquired NextWave Pharmaceuticals from Pfizer Inc., giving it a pair of key attention deficit hyperactivity disorder treatments, it announced Tuesday.
The deal is expected to bolster Tris’ portfolio of ADHD treatments, giving it Quillivant XR and QuilliChew ER, a pair of approved central nervous system stimulants.
Tris co-developed the products with NextWave, which was acquired by Pfizer in 2012, and manufactured them for the larger drugmaker.
“As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialization of these products in-house and expand our ADHD portfolio,” Tris CEO and President Ketan Mehta said in a prepared statement. “To further support our newest acquisition, Tris is expanding our commercial footprint and building a world-class medical affairs group.”
Financial terms of the deal were not disclosed.
